Literature DB >> 31958095

Soluble TREM2 and Inflammatory Proteins in Alzheimer's Disease Cerebrospinal Fluid.

Boris-Stephan Rauchmann1,2, Angélique Sadlon3, Robert Perneczky2,3,4,5.   

Abstract

The present study explores the associations of soluble TREM2, an important regulator of microglial activity linked to Alzheimer's disease (AD), with other known inflammatory proteins in cerebrospinal fluid (CSF). We studied 303 participants, including 89 controls, 135 mild cognitive impairment, and 79 AD dementia patients. Using established CSF biomarkers, subjects were classified according to the National Institute on Aging-Alzheimer's Association research framework, which groups markers into those of amyloid-β deposition (A), tau pathology (T), and neurodegeneration (N). TNFR1, TNFR2, TGF-β1, TGFβ2, IL-9, TNF-α, ICAM1, and VCAM1 showed significant concentration differences between the ATN groups, with higher concentrations in more advanced disease categories. sTREM2 was positively associated with the pro-inflammatory proteins TNF-α, TNFR1, TNFR2, ICAM1, VCAM1, and IP-10 and negatively with IL-21; also, positive associations with the anti-inflammatory proteins TGFβ1, IL-10, and IL-9 were found. Pathway enrichment analysis highlighted the involvement of sTREM2 in key functional clusters including immunoglobulin and cytokine production and cellular response to lipopolysaccharides, cytokines, and steroid hormones. Our work provides further evidence in support of TREM2 as amarker of neuroinflammatory response in AD.

Entities:  

Keywords:  Alzheimer’s disease; biomarker; functional annotation; interactions zzm321990network; neurodegeneration; neuroinflammation

Mesh:

Substances:

Year:  2020        PMID: 31958095     DOI: 10.3233/JAD-191120

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  11 in total

Review 1.  Biological aging processes underlying cognitive decline and neurodegenerative disease.

Authors:  Mitzi M Gonzales; Valentina R Garbarino; Erin Pollet; Juan P Palavicini; Dean L Kellogg; Ellen Kraig; Miranda E Orr
Journal:  J Clin Invest       Date:  2022-05-16       Impact factor: 19.456

Review 2.  TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target.

Authors:  Rui-Yang Li; Qi Qin; Han-Chen Yang; Ying-Ying Wang; Ying-Xin Mi; Yun-Si Yin; Meng Wang; Chao-Ji Yu; Yi Tang
Journal:  Mol Neurodegener       Date:  2022-06-03       Impact factor: 18.879

Review 3.  Knowledge gaps in Alzheimer's disease immune biomarker research.

Authors:  David G Morgan; Michelle M Mielke
Journal:  Alzheimers Dement       Date:  2021-05-13       Impact factor: 21.566

4.  TREM2 alters the phagocytic, apoptotic and inflammatory response to Aβ42 in HMC3 cells.

Authors:  Rumana Akhter; Yvonne Shao; Shane Formica; Maria Khrestian; Lynn M Bekris
Journal:  Mol Immunol       Date:  2021-01-15       Impact factor: 4.407

Review 5.  TREM2 ectodomain and its soluble form in Alzheimer's disease.

Authors:  Jiaolong Yang; Zhihui Fu; Xingyu Zhang; Min Xiong; Lanxia Meng; Zhentao Zhang
Journal:  J Neuroinflammation       Date:  2020-07-07       Impact factor: 8.322

Review 6.  Does Soluble TREM2 Protect Against Alzheimer's Disease?

Authors:  Guy C Brown; Peter St George-Hyslop
Journal:  Front Aging Neurosci       Date:  2022-01-28       Impact factor: 5.750

Review 7.  The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease.

Authors:  Martí Colom-Cadena; Tara Spires-Jones; Henrik Zetterberg; Kaj Blennow; Anthony Caggiano; Steven T DeKosky; Howard Fillit; John E Harrison; Lon S Schneider; Phillip Scheltens; Willem de Haan; Michael Grundman; Christopher H van Dyck; Nicholas J Izzo; Susan M Catalano
Journal:  Alzheimers Res Ther       Date:  2020-03-02       Impact factor: 6.982

8.  Role of RPTPβ/ζ in neuroinflammation and microglia-neuron communication.

Authors:  Rosalía Fernández-Calle; Milagros Galán-Llario; Esther Gramage; Begoña Zapatería; Marta Vicente-Rodríguez; José M Zapico; Beatriz de Pascual-Teresa; Ana Ramos; M Pilar Ramos-Álvarez; María Uribarri; Marcel Ferrer-Alcón; Gonzalo Herradón
Journal:  Sci Rep       Date:  2020-11-20       Impact factor: 4.379

9.  Associations of cerebrospinal fluid amyloidogenic nanoplaques with cytokines in Alzheimer's disease.

Authors:  Mari Aksnes; Hans Christian D Aass; Ann Tiiman; Trine Holt Edwin; Lars Terenius; Nenad Bogdanović; Vladana Vukojević; Anne-Brita Knapskog
Journal:  Transl Neurodegener       Date:  2021-06-08       Impact factor: 8.014

10.  Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer's disease.

Authors:  William T Hu; Tugba Ozturk; Alexander Kollhoff; Whitney Wharton; J Christina Howell
Journal:  Nat Commun       Date:  2021-06-28       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.